May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Glu–Tyr polypeptide (Poly–YE) vaccination for acute and chronic glaucoma
Author Affiliations & Notes
  • S. Bakalash
    Neurobiology, Weizmann Institute of Science, Rehovot, Israel
  • E. Yoles
    Proneuron Biotechnologies, Ness Ziona, Israel
  • Y. Geffen
    Proneuron Biotechnologies, Ness Ziona, Israel
  • M. Schwartz
    Neurobiology, Weizmann Institute of Science, Rehovot, Israel
  • Footnotes
    Commercial Relationships  S. Bakalash, None; E. Yoles, None; Y. Geffen, None; M. Schwartz, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 910. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Bakalash, E. Yoles, Y. Geffen, M. Schwartz; Glu–Tyr polypeptide (Poly–YE) vaccination for acute and chronic glaucoma . Invest. Ophthalmol. Vis. Sci. 2004;45(13):910.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Background: T cells directed against self–antigens facilitate survival and repair following central nervous system (CNS) injury. Such a protective mechanism is amenable for boosting by active immunization with weak agonists of self–antigens. Here we examined whether a similar neuroprotective effect can be evoked by vaccination with a random copolymer of two amino acids, consisting of only glutamic acid and tyrosine. Methods: Intraocular pressure (IOP) in the rat was unilaterally elevated by lasering of ocular blood vessels (chronic model) or by saline infusion into the anterior chamber (acute model). IOP was measured with Tono–Pen (XL, Mentor®). After IOP elevation, poly–YE or PBS only was administered according to different regimens. IOP–generated damage was assessed after 1 or 2 weeks in the acute model, and after 3 weeks in the chronic model, by retrograde labeling of viable retinal ganglion cells (RGCs) with rhodamine dextran. Vaccinated and control rats were also subjected to immunohistochemical staining for detection of T cells (alpha beta TCR) at several time points after acute elevation of IOP. Results: In the acute glaucoma model, poly–YE vaccination evoked an early, well–controlled increase in local T cell accumulation, which subsided by day 7, and resulted in survival of significantly more RGCs than in control rats (77±6% compared to 46±11%, P<0.05). Vaccination was effective only when given within 24 h of IOP elevation. Similar extents of survival were observed in the chronic IOP model (72.6±4.37% compared to 51.48±1.68%) and with other routes of administration (e.g. eyedrops). Conclusions: Vaccination with Poly–YE was neuroprotective in two glaucoma models. Poly–YE is effective apparently through regulation of local microglia.

Keywords: autoimmune disease • inflammation • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×